Visiting Scientist Eleftheria Hatzimichael

Visiting Scientist

Short Bio

Eleftheria Hatzimichael, MD, PhD (born 1975) is a Haematologist, with a strong background and research activities in epigenetics and translational research. She graduated from the School of Medicine, University of Ioannina in 1998 and was trained in Haematology at St. Bartholomew’s Hospital, Barts and the London Trust, London, UK and the University Hospital of Ioannina, Ioannina, Greece. For her achievements she was recently been awarded a prestigious early-carrier one-year fellowship from the Hellenic Society of Haematology Foundation to work with Dr Isidore Rigoutsos as Visiting Scientist at the Computational Medicine Centre, Sidney Kimmel Medical College, Thomas Jefferson University, US, in the field of non-coding human genome by computational and experimental approaches. She is currently a Consultant Haematologist and the Clinical and Translational Research Leader in the Department of Haematology, University Hospital of Ioannina, Ioannina, Greece and co-investigator in more than 10 phase I-III clinical trials. She has served as a reviewer in 7 journals and she is a member of the Associate Editorial Board of the American Journal of Blood Research.

Publications

Papers

 

2015

  • Papoudou-Bai, A, Hatzimichael, E, Kyriazopoulou, L, Briasoulis, E, Kanavaros, P. Rare variants in the spectrum of human herpesvirus 8/Epstein-Barr virus-copositive lymphoproliferations. Hum. Pathol. 2015;46 (10):1566-71. doi: 10.1016/j.humpath.2015.06.020. PubMed PMID:26299509.
  • Londin, E, Loher, P, Telonis, AG, Quann, K, Clark, P, Jing, Y, Hatzimichael, E, Kirino, Y, Honda, S, Lally, M, Ramratnam, B, Comstock, CE, Knudsen, KE, Gomella, L, Spaeth, GL, Hark, L, Katz, LJ, Witkiewicz, A, Rostami, A, Jimenez, SA, Hollingsworth, MA, Yeh, JJ, Shaw, CA, McKenzie, SE, Bray, P, Nelson, PT, Zupo, S, Van Roosbroeck, K, Keating, MJ, Calin, GA, Yeo, C, Jimbo, M, Cozzitorto, J, Brody, JR, Delgrosso, K, Mattick, JS, Fortina, P, Rigoutsos, I. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc. Natl. Acad. Sci. U.S.A. 2015;112 (10):E1106-15. doi: 10.1073/pnas.1420955112. PubMed PMID:25713380 PubMed Central PMC4364231.

2014

  • Primikyri, A, Chatziathanasiadou, MV, Karali, E, Kostaras, E, Mantzaris, MD, Hatzimichael, E, Shin, JS, Chi, SW, Briasoulis, E, Kolettas, E, Gerothanassis, IP, Tzakos, AG. Direct binding of Bcl-2 family proteins by quercetin triggers its pro-apoptotic activity. ACS Chem. Biol. 2014;9 (12):2737-41. doi: 10.1021/cb500259e. PubMed PMID:25211642.
  • Hatzimichael, E, Tsolas, E, Briasoulis, E. Profile of pacritinib and its potential in the treatment of hematologic disorders. J Blood Med. 2014;5 :143-52. doi: 10.2147/JBM.S51253. PubMed PMID:25170285 PubMed Central PMC4145824.
  • Benetatos, L, Vartholomatos, G, Hatzimichael, E. DLK1-DIO3 imprinted cluster in induced pluripotency: landscape in the mist. Cell. Mol. Life Sci. 2014;71 (22):4421-30. doi: 10.1007/s00018-014-1698-9. PubMed PMID:25098353.
  • Hatzimichael, E, Syed, N, Lo Nigro, C, Crook, T. A blood test to identify when melanoma metastasizes: a reality for melanoma management?. Melanoma Manag. 2014;1 (1):11-14. doi: 10.2217/mmt.14.11. PubMed PMID:30190804 PubMed Central PMC6094697.
  • Benetatos, L, Hatzimichael, E. Delta-like homologue 1 and its role in the bone marrow niche and hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2014;14 (6):451-5. doi: 10.1016/j.clml.2014.06.019. PubMed PMID:25066037.
  • Hatzimichael, E, Syed, N, Lo Nigro, C, Rao, B, Crook, T. How detection of epigenetic alterations of blood-borne DNA could improve melanoma diagnosis. Expert Rev. Mol. Diagn. 2014;14 (6):639-42. doi: 10.1586/14737159.2014.928204. PubMed PMID:24926921.
  • Kastritis, E, Zagouri, F, Symeonidis, A, Roussou, M, Sioni, A, Pouli, A, Delimpasi, S, Katodritou, E, Michalis, E, Michael, M, Hatzimichael, E, Vassou, A, Repousis, P, Christophoridou, A, Kartasis, Z, Stefanoudaki, E, Megalakaki, C, Giannouli, S, Kyrtsonis, MC, Konstantopoulos, K, Spyroupoulou-Vlachou, M, Terpos, E, Dimopoulos, MA, Greek Myeloma Study Group. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia. 2014;28 (10):2075-9. doi: 10.1038/leu.2014.110. PubMed PMID:24637336.
  • Londin, ER, Hatzimichael, E, Loher, P, Edelstein, L, Shaw, C, Delgrosso, K, Fortina, P, Bray, PF, McKenzie, SE, Rigoutsos, I. The human platelet: strong transcriptome correlations among individuals associate weakly with the platelet proteome. Biol. Direct. 2014;9 :3. doi: 10.1186/1745-6150-9-3. PubMed PMID:24524654 PubMed Central PMC3937023.
  • Hatzimichael, E, Lagos, K, Sim, VR, Briasoulis, E, Crook, T. Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update. EXCLI J. 2014;13 :954-76. PubMed PMID:26417314 PubMed Central PMC4464089.
  • Benetatos, L, Vartholomatos, G, Hatzimichael, E. Polycomb group proteins and MYC: the cancer connection. Cell. Mol. Life Sci. 2014;71 (2):257-69. doi: 10.1007/s00018-013-1426-x. PubMed PMID:23897499.
  • Katodritou, E, Vadikolia, C, Lalagianni, C, Kotsopoulou, M, Papageorgiou, G, Kyrtsonis, MC, Matsouka, P, Giannakoulas, N, Kyriakou, D, Karras, G, Anagnostopoulos, N, Michali, E, Briasoulis, E, Hatzimichael, E, Spanoudakis, E, Zikos, P, Tsakiridou, A, Tsionos, K, Anargyrou, K, Symeonidis, A, Maniatis, A, Terpos, E. "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. Ann. Hematol. 2014;93 (1):129-39. doi: 10.1007/s00277-013-1841-y. PubMed PMID:23892921.

2013

  • Hatzimichael, E, Murray, S, Briasoulis, E. Absence of BRAF exon 15 mutations in multiple myeloma and Waldenström"s macroglobulinemia questions its validity as a therapeutic target in plasma cell neoplasias. Am J Blood Res. 2013;3 (2):181-5. PubMed PMID:23675568 PubMed Central PMC3649814.
  • Hatzimichael, E, Crook, T. Cancer epigenetics: new therapies and new challenges. J Drug Deliv. 2013;2013 :529312. doi: 10.1155/2013/529312. PubMed PMID:23533770 PubMed Central PMC3600296.
  • Benetatos, L, Hatzimichael, E, Londin, E, Vartholomatos, G, Loher, P, Rigoutsos, I, Briasoulis, E. The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis. Cell. Mol. Life Sci. 2013;70 (5):795-814. doi: 10.1007/s00018-012-1080-8. PubMed PMID:22825660.

2012

  • Hatzimichael, E, Lo Nigro, C, Lattanzio, L, Syed, N, Shah, R, Dasoula, A, Janczar, K, Vivenza, D, Monteverde, M, Merlano, M, Papoudou-Bai, A, Bai, M, Schmid, P, Stebbing, J, Bower, M, Dyer, MJ, Karran, LE, ElguetaKarstegl, C, Farrell, PJ, Thompson, A, Briasoulis, E, Crook, T. The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. Br. J. Cancer. 2012;107 (8):1423-32. doi: 10.1038/bjc.2012.380. PubMed PMID:22955849 PubMed Central PMC3494450.
  • Delage, B, Luong, P, Maharaj, L, O"Riain, C, Syed, N, Crook, T, Hatzimichael, E, Papoudou-Bai, A, Mitchell, TJ, Whittaker, SJ, Cerio, R, Gribben, J, Lemoine, N, Bomalaski, J, Li, CF, Joel, S, Fitzgibbon, J, Chen, LT, Szlosarek, PW. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis. 2012;3 :e342. doi: 10.1038/cddis.2012.83. PubMed PMID:22764101 PubMed Central PMC3406582.
  • Lo Nigro, C, Monteverde, M, Lee, S, Lattanzio, L, Vivenza, D, Comino, A, Syed, N, McHugh, A, Wang, H, Proby, C, Garrone, O, Merlano, M, Hatzimichael, E, Briasoulis, E, Gojis, O, Palmieri, C, Jordan, L, Quinlan, P, Thompson, A, Crook, T. NT5E CpG island methylation is a favourable breast cancer biomarker. Br. J. Cancer. 2012;107 (1):75-83. doi: 10.1038/bjc.2012.212. PubMed PMID:22653144 PubMed Central PMC3389412.
  • Dranitsaris, G, Hatzimichael, E. Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. Support Care Cancer. 2012;20 (7):1353-60. doi: 10.1007/s00520-012-1461-4. PubMed PMID:22539050 PubMed Central PMC3360851.
  • Dimopoulos, MA, Kastritis, E, Delimpasi, S, Katodritou, E, Hatzimichael, E, Kyrtsonis, MC, Repousis, P, Tsirogianni, M, Kartasis, Z, Parcharidou, A, Michael, M, Michalis, E, Tsatalas, C, Stefanoudaki, E, Hatjiharissi, E, Gika, D, Symeonidis, A, Terpos, E, Zervas, K, Greek Myeloma Study Group. Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era. Eur. J. Haematol. 2012;89 (1):10-5. doi: 10.1111/j.1600-0609.2012.01784.x. PubMed PMID:22469521.
  • Wang, H, Lee, S, Nigro, CL, Lattanzio, L, Merlano, M, Monteverde, M, Matin, R, Purdie, K, Mladkova, N, Bergamaschi, D, Harwood, C, Syed, N, Szlosarek, P, Briasoulis, E, McHugh, A, Thompson, A, Evans, A, Leigh, I, Fleming, C, Inman, GJ, Hatzimichael, E, Proby, C, Crook, T. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br. J. Cancer. 2012;106 (8):1446-52. doi: 10.1038/bjc.2012.95. PubMed PMID:22454080 PubMed Central PMC3326678.
  • Coley, HM, Hatzimichael, E, Blagden, S, McNeish, I, Thompson, A, Crook, T, Syed, N. Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer. Oncotarget. 2012;3 (1):78-83. doi: 10.18632/oncotarget.332. PubMed PMID:22289679 PubMed Central PMC3292894.
  • Hatzimichael, E, Dasoula, A, Kounnis, V, Benetatos, L, Lo Nigro, C, Lattanzio, L, Papoudou-Bai, A, Dranitsaris, G, Briasoulis, E, Crook, T. Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications. Leuk. Lymphoma. 2012;53 (9):1709-13. doi: 10.3109/10428194.2012.661854. PubMed PMID:22288719.

2011

  • Tzakos, AG, Fokas, D, Johannes, C, Moussis, V, Hatzimichael, E, Briasoulis, E. Targeting oncogenic protein-protein interactions by diversity oriented synthesis and combinatorial chemistry approaches. Molecules. 2011;16 (6):4408-27. doi: 10.3390/molecules16064408. PubMed PMID:21623312.
  • Syed, N, Coley, HM, Sehouli, J, Koensgen, D, Mustea, A, Szlosarek, P, McNeish, I, Blagden, SP, Schmid, P, Lovell, DP, Hatzimichael, E, Crook, T. Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res. 2011;71 (9):3317-27. doi: 10.1158/0008-5472.CAN-10-2048. PubMed PMID:21402713.
  • Benetatos, L, Vartholomatos, G, Hatzimichael, E. MEG3 imprinted gene contribution in tumorigenesis. Int. J. Cancer. 2011;129 (4):773-9. doi: 10.1002/ijc.26052. PubMed PMID:21400503.
  • Benetatos, L, Dasoula, A, Hatzimichael, E, Syed, N, Voukelatou, M, Dranitsaris, G, Bourantas, KL, Crook, T. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions. Ann. Hematol. 2011;90 (9):1037-45. doi: 10.1007/s00277-011-1193-4. PubMed PMID:21340720.

2010

  • Hatzimichael, E, Dasoula, A, Benetatos, L, Syed, N, Dranitsaris, G, Crook, T, Bourantas, K. Study of specific genetic and epigenetic variables in multiple myeloma. Leuk. Lymphoma. 2010;51 (12):2270-4. doi: 10.3109/10428194.2010.528095. PubMed PMID:21067440.

2009

  • Chaliasos, N, Challa, A, Hatzimichael, E, Koutsouka, F, Bourantas, DK, Vlahos, AP, Siamopoulou, A, Bourantas, KL, Makis, A. Serum adipocytokine and vascular inflammation marker levels in Beta-thalassaemia major patients. Acta Haematol. 2010;124 (4):191-6. doi: 10.1159/000320274. PubMed PMID:21042009.
  • Makis, A, Shipway, D, Hatzimichael, E, Galanakis, E, Pshezhetskiy, D, Chaliasos, N, Stebbing, J, Siamopoulou, A. Cytokine and adhesion molecule expression evolves between the neutrophilic and lymphocytic phases of viral meningitis. J. Interferon Cytokine Res. 2010;30 (9):661-5. doi: 10.1089/jir.2009.0113. PubMed PMID:20626298.
  • Lee, S, Syed, N, Taylor, J, Smith, P, Griffin, B, Baens, M, Bai, M, Bourantas, K, Stebbing, J, Naresh, K, Nelson, M, Tuthill, M, Bower, M, Hatzimichael, E, Crook, T. DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt"s lymphoma. Br. J. Cancer. 2010;103 (2):265-74. doi: 10.1038/sj.bjc.6605711. PubMed PMID:20551953 PubMed Central PMC2906728.
  • Hatzimichael, E, Tuthill, M. Hematopoietic stem cell transplantation. Stem Cells Cloning. 2010;3 :105-17. doi: 10.2147/SCCAA.S6815. PubMed PMID:24198516 PubMed Central PMC3781735.
  • Ximeri, M, Galanopoulos, A, Klaus, M, Parcharidou, A, Giannikou, K, Psyllaki, M, Symeonidis, A, Pappa, V, Kartasis, Z, Liapi, D, Hatzimichael, E, Kokoris, S, Korkolopoulou, P, Sambani, C, Pontikoglou, C, Papadaki, HA, Hellenic MDS Study Group. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica. 2010;95 (3):406-14. doi: 10.3324/haematol.2009.010876. PubMed PMID:19773257 PubMed Central PMC2833070.
  • Hatzimichael, E, Dasoula, A, Shah, R, Syed, N, Papoudou-Bai, A, Coley, HM, Dranitsaris, G, Bourantas, KL, Stebbing, J, Crook, T. The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. Eur. J. Haematol. 2010;84 (1):47-51. doi: 10.1111/j.1600-0609.2009.01344.x. PubMed PMID:19737309.
  • Benetatos L, Hatzimichael E, Dasoula A, Dranitsaris G, Tsiara S, Syrrou M, Georgiou I, Bourantas KL. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2010 Feb;34(2):148-53. doi: 10.1016/j.leukres.2009.06.019. PubMed PMID:19595458.
  • Hatzimichael, E, Dranitsaris, G, Dasoula, A, Benetatos, L, Stebbing, J, Crook, T, Bourantas, KL. Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease. Clin Lymphoma Myeloma. 2009;9 (3):239-42. doi: 10.3816/CLM.2009.n.047. PubMed PMID:19525194.
  • Hatzimichael, E, Benetatos, L, Dasoula, A, Dranitsaris, G, Tsiara, S, Georgiou, I, Syrrou, M, Stebbing, J, Coley, HM, Crook, T, Bourantas, KL. Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia. Leuk. Res. 2009;33 (9):1272-5. doi: 10.1016/j.leukres.2009.04.009. PubMed PMID:19423161.
  • Powles, T, Stebbing, J, Bazeos, A, Hatzimichael, E, Mandalia, S, Nelson, M, Gazzard, B, Bower, M. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman"s disease. Ann. Oncol. 2009;20 (4):775-9. doi: 10.1093/annonc/mdn697. PubMed PMID:19179554.
  • Descamps, M, Hatzimichael, E, Bhuva, N, Stebbing, J. Radiological imaging in the context of HIV infection: size of the lesion is not everything. J HIV Ther. 2008;13 (3):47-8. PubMed PMID:19039294.

2008

  • Benetatos, L, Dasoula, A, Hatzimichael, E, Georgiou, I, Syrrou, M, Bourantas, KL. Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma. Clin Lymphoma Myeloma. 2008;8 (3):171-5. doi: 10.3816/CLM.2008.n.021. PubMed PMID:18650181.
  • Hatzimichael, E, Dasoula, A, Benetatos, L, Makis, A, Stebbing, J, Crook, T, Syrrou, M, Bourantas, KL. The absence of CDKN1C (p57KIP2) promoter methylation in myeloid malignancies also characterizes plasma cell neoplasms. Br. J. Haematol. 2008;141 (4):557-8. doi: 10.1111/j.1365-2141.2008.07034.x. PubMed PMID:18371112.
  • Benetatos, L, Dasoula, A, Syed, N, Hatzimichael, E, Crook, T, Bourantas, KL. Methylation analysis of the von Hippel-Lindau gene in acute myeloid leukaemia and myelodysplastic syndromes. Leukemia. 2008;22 (6):1293-5. doi: 10.1038/sj.leu.2405053. PubMed PMID:18094722.

2007

  • Panteli, K, Bai, M, Hatzimichael, E, Zagorianakou, N, Agnantis, NJ, Bourantas, K. Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases. Hematology. 2007;12 (6):481-6. doi: 10.1080/10245330701554664. PubMed PMID:17852434.

2006

  • Benetatos, L, Hatzimichael, E, Vassou, A, Bourantas, KL. Cryptococcus lung infection complicating fludarabine treatment in a chronic lymphocytic leukemia patient. Leuk. Res. 2007;31 (1):119-20. doi: 10.1016/j.leukres.2006.03.008. PubMed PMID:16620969.
  • Winston, A, Hatzimichael, E, Marvin, V, Stebbing, J, Bower, M. Host pharmacogenetics in the treatment of HIV and cancer. Curr Drug Saf. 2006;1 (1):107-16. PubMed PMID:18690920.
  • Hatzimichael, E, Benetatos, L, Stebbing, J, Kapsali, E, Panayiotopoulou, S, Bourantas, KL. Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support. Clin Lab Haematol. 2006;28 (6):416-8. doi: 10.1111/j.1365-2257.2006.00819.x. PubMed PMID:17105496.
  • Makis, AC, Hatzimichael, EC, Stebbing, J. The genomics of new drugs in sickle cell disease. Pharmacogenomics. 2006;7 (6):909-17. doi: 10.2217/14622416.7.6.909. PubMed PMID:16981849.
  • Makis, AC, Hatzimichael, EC, Stebbing, J, Bourantas, KL. C-reactive protein and vascular cell adhesion molecule-1 as markers of severity in sickle cell disease. Arch. Intern. Med. 2006;166 (3):366-8. doi: 10.1001/archinte.166.3.366. PubMed PMID:16476879.
  • Stebbing, J, Mazhar, D, Lewis, R, Palmieri, C, Hatzimichael, E, Nelson, M, Gazzard, B, Bower, M. The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi"s sarcoma. Ann. Oncol. 2006;17 (3):503-6. doi: 10.1093/annonc/mdj091. PubMed PMID:16311274.

2005

  • Stebbing, J, Hatzimichael, E, Bower, M, Winston, A. The rationale and development of new drugs to treat HIV infection. Med Chem. 2005;1 (6):635-42. PubMed PMID:16787347.

2004

  • Makis, AC, Galanakis, E, Hatzimichael, EC, Papadopoulou, ZL, Siamopoulou, A, Bourantas, KL. Serum levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) as a predictor of outcome in brucellosis. J. Infect. 2005;51 (3):206-10. doi: 10.1016/j.jinf.2004.10.013. PubMed PMID:16230217.
  • Panteli, KE, Hatzimichael, EC, Bouranta, PK, Katsaraki, A, Seferiadis, K, Stebbing, J, Bourantas, KL. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br. J. Haematol. 2005;130 (5):709-15. doi: 10.1111/j.1365-2141.2005.05674.x. PubMed PMID:16115126.
  • Sfagos, C, Makis, AC, Chaidos, A, Hatzimichael, EC, Dalamaga, A, Kosma, K, Bourantas, KL. Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients. Mult. Scler. 2005;11 (3):272-5. doi: 10.1191/1352458505ms1171oa. PubMed PMID:15957506.
  • Chaidos, A, Makis, A, Hatzimichael, E, Tsiara, S, Gouva, M, Tzouvara, E, Bourantas, KL. Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. Acta Haematol. 2004;111 (4):189-95. doi: 10.1159/000077551. PubMed PMID:15153710.
  • Makis, AC, Hatzimichael, EC, Kolios, G, Bourantas, KL. Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment. Haematologica. 2004;89 (3):360-1. PubMed PMID:15020278.

2001

  • Makis, AC, Chaliasos, N, Hatzimichael, EC, Bourantas, KL. Recombinant human erythropoietin therapy in a transfusion-dependent beta-thalassemia major patient. Ann. Hematol. 2001;80 (8):492-5. PubMed PMID:11563599.
  • Christou, L, Hatzimichael, E, Chaidos, A, Tsiara, S, Bourantas, KL. Treatment of plasma cell leukemia with vincristine, liposomal doxorubicin and dexamethasone. Eur. J. Haematol. 2001;67 (1):51-3. PubMed PMID:11553267.
  • Voulgari, PV, Hatzimichael, EC, Tsiara, S, Tzallas, C, Drosos, AA, Bourantas, KL. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes. Eur. J. Haematol. 2001;66 (1):31-6. PubMed PMID:11168505.
  • Hatzimichael, EC, Christou, L, Bai, M, Kolios, G, Kefala, L, Bourantas, KL. Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenström"s macroglobulinemia. Eur. J. Haematol. 2001;66 (1):1-6. PubMed PMID:11168500.

2000 And Earlier

  • Makis, AC, Hatzimichael, EC, Mavridis, A, Bourantas, KL. Alpha-2-macroglobulin and interleukin-6 levels in steady-state sickle cell disease patients. Acta Haematol. 2000;104 (4):164-8. doi: 10.1159/000046509. PubMed PMID:11279305.
  • Makis, AC, Hatzimichael, EC, Bourantas, KL. The role of cytokines in sickle cell disease. Ann. Hematol. 2000;79 (8):407-13. PubMed PMID:10985359.
  • Bourantas, KL, Hatzimichael, EC, Makis, AC, Kapsali, E, Tsiara, S, Christou, L, Seferiadis, K. Prolonged interferon-alpha-2b treatment of hairy cell leukemia patients. Eur. J. Haematol. 2000;64 (5):350-1. PubMed PMID:10863983.
  • Bourantas, KL, Xenakis, TA, Hatzimichael, EC, Kontogeorgakos, V, Beris, AE. Peri-operative use of recombinant human erythropoietin in Jehovah"s Witnesses. Haematologica. 2000;85 (4):444-5. PubMed PMID:10756382.
  • Christou, L, Hatzimichael, EC, Sotsiou-Candila, F, Siamopoulos, K, Bourantas, KL. A patient with multiple myeloma, amyloidosis and light-chain deposition disease in kidneys with a long survival. Acta Haematol. 1999;101 (4):202-5. doi: 10.1159/000040954. PubMed PMID:10436302.
  • Bourantas, KL, Hatzimichael, EC, Makis, AC, Chaidos, A, Kapsali, ED, Tsiara, S, Mavridis, A. Serum beta-2-microglobulin, TNF-alpha and interleukins in myeloproliferative disorders. Eur. J. Haematol. 1999;63 (1):19-25. PubMed PMID:10414450.

To see the group's publications please click here or go to Research -> Publications

Contact Info